富瑞:降百威亞太(1876.HK)目標至30港元 但稱現時是買入良機
富瑞發表研究報告指,現時或可以最低價格買入百威亞太(1876.HK)股份,預計隨着夜生活需求的恢復,下半年回報將出現積極增長,復甦勢頭將超過同行。該行將其目標價從32港元下調至30港元,較前收市價仍有上行42%的空間。
富瑞指,百威最近幾個月在零售和電子商務渠道中的市場份額也有所增加,這將有助於需求恢復時的增長,由於第一季度業績遜於預期,遂將百威2020年銷售和淨利預期分別下調3%和11%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.